Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Michela Gallagher
Johns Hopkins University, Department: Psychology
Should you be removed from our database? Contact us at [email protected]. Read more below.
AgeneBio, Inc.
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution
The R01 funds a human subjects research clinical trial involving the intellectual property, a novel therapeutic, that is licensed to AgeneBio, a company that the investigator founded. The SFIs that result from the income, intellectual property rights, and equity interest in a privately held entity are related in that their value could be affected by the research. The SFI that results from the fiduciary role is related in that it is in an entity whose financial interest could be affected by the research. Upon review by the institution, it was determined that Dr. Gallagher's SFIs could directly and significantly affect the design, conduct or reporting of her research under this award.
PHASE II/III trial for Slowing Progression in Mild Cognitive Impairment
Prevention or slowing the progression of Alzheimer's dementia would address a critical unmet need that will otherwise significantly burden patients, caregivers and the healthcare system in the decades ahead. Using a low dose of levetiracetam in a once-a- day formulation, a drug approved as safe and well-tolerated at much higher dosing in epilepsy patients, this clinical trial assesses the efficacy of two-year therapy in slowing the progression of amnestic mild cognitive impairment due to AD. The study uses endpoints consistent with regulatory guidance for this indication and will produce publically available data that can be used to advance AD prevention trial design and biomarker development, in addition testing a novel approach to Alzheimer's disease in patients at high risk for dementia.
Filed on June 07, 2019.
Tell us what you know about Michela Gallagher's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Michela Gallagher filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Michela Gallagher | Johns Hopkins University | Conflict of Interest | AgeneBio, Inc. | Value cannot be readily determined |
| Michela Gallagher | Johns Hopkins University | Conflict of Interest | AgeneBio, Inc. | Value cannot be readily determined |
| Michela Gallagher | Johns Hopkins University | Conflict of Interest | AgeneBio, Inc. | Value cannot be readily determined |
| Michela Gallagher | Johns Hopkins University | Conflict of Interest | AgeneBio, Inc. | Value cannot be readily determined |
| Michela Gallagher | Johns Hopkins University | Conflict of Interest | AgeneBio, Inc. | Value cannot be readily determined |
| Michela Gallagher | Johns Hopkins University | Conflict of Interest | AgeneBio, Inc. | Value cannot be readily determined |
| Michela Gallagher | Johns Hopkins University | Conflict of Interest | AgeneBio, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.